← Back to Treatments
🏅 FDA Orphan Designation

Wayrilz

rilzabrutinib

Manufacturer: Genzyme Corporation (A Sanofi Company)

Indicated for:
Immune thrombocytopeniaOrphan

FDA-Approved Indications (1)

Immune thrombocytopeniaOrphan Designation

treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

Indications & Usage

1 INDICATIONS AND USAGE WAYRILZ is indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. WAYRILZ is a kinase inhibitor indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. ( 1 )

💙 Support Programs

View all →
Wayrilz
Genzyme Corporation (A Sanofi Company)
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.